CPHI - Earnings call transcript Q4 2017 | China Pharma Holdings, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by and welcome to China Pharma Holdings' Incorporated Full Year 2017 Earnings Conference Call. At this time all participants are in a listen only mode. There will be a presentation followed by a question-and-answer session. [Operator Instructions] Please be advice that this conference is being recorded today, Tuesday, 3rd of April 2018. I would now like to hand the conference over to your first speaker today, Ms. Huang. Diana go please ahead. you, Thank

Diana Huang

full you, morning the good Welcome company's and conference Holdings’ and Investor Relations Good to Thank to I'm those Huang, Pharma China. ladies evening from of gentlemen, us earnings operator. you Diana XXXX year Manager. China call. joining

and and Speaking President, Corporate President China Mr. on CFO, Interim Sam are today and the Vice Ms. call Hsing. Pharma's CEO Zhilin Li;

response today the ability our and operating our regulatory other requisite sales SEC. with the product discussed to the press ability like questions. develop company customer call. release to detailed of Safe Reform and approvals market our our timely provide a will the and during obtain environment Development Q&A product, The translation remarks the the as new risks is the company's statements, regulatory the in to results on on spending including including your www.chinapharmaholdings.com. market protection of earnings our to our uncertainties and time-to-time contain earlier results XXXX. in the In risks claims to Litigation website demands for Securities addition, differ products, subject I those from which in for Act prepared is may for that contained such available acceptance and products, issued activities, impact session of in commercialize the regulation call, the that fluctuations in PRC, morning Research on filings Actual government product forward-looking marketing to make this Private at our and statements ability of due Harbor pricing, competitive risks management management's listeners Therefore, are from and and forward-looking launch statements this and additional forward-looking to basis, to the our may and I remind would

the as estimates represent update China future market X, the of projections obligation as XXXX. company's as in management's In future Pharma to addition, change. assumes projections today, conditions any to performance no April those

is my then Ms. Li’s her Sam Li over the by company's call Chinese, will translating will full results. be China Sam. XXXX the and financial it make Now, turn continue opening Afterwards, detailed discussion Pharma's pleasure remarks Interim which CEO translated to in CFO, to to of year Ms.

Zhilin Li

to and consistency and products evaluated the return the policy, time demand, actively of impairment evaluation recognize reach technical company significant of all and fast as offers of pipeline ongoing continue production of was top and have medical participation drug industry sales expected. sales would increasing in The its active China's new and research Thank of XXXX, thank I the we requirements of to development you the promote in patterns. you, and the and business reform major the further evaluations provincial consistency the so and drug recovery the market joining basic our requirements in tender the the loss Investment Nevertheless, We sales receive impact the speed tried of products generic today not everyone. difficulty. intangible applicable our the like change openings as us support policies sales remains Diana, each will the morning registration priority. China to future may good market. increase for on our for your to Pharma. the and market related will but Under recent to through review asset of Management XXXX. continued rigorously drug investment our

English. of current the products, now Ms. I We conditions development the order in further will and read strategies. existing pipeline adapt will to market continue in and competition our remarks to our to state evaluate in rest actively policy market guidance optimize Li's for prepared products,

XXXX, This like I decrease to full XXXX. year balance to ended December $XX.X December review XXXX for million the sheet by XX, XX, year million decreased Now compared the our XX.X% due ended results impact XXXX. the year well December mainly information. financial would insurance as Revenue healthcare and to $XX.X around to health-care for the proportion the Gross to for to policies reducing cost as cost-control $X.X compared drug the $X.X was was profit spending. million negative of XXXX XX, total year-ended as in for million,

gross margin requirements. profit to Our with the our and prices industry compared the generally of the to have mainly XXXX. due improvement in decline XX.X% was XXXX XX.X% gross that the margin raw in quarters in of profit material in This standards screening along was increased protection recent our environmental

adverse addition, negatively policies drug our pricing have margins. impacted control In gross

Chinese were for the $X.X revenue in expenses XXXX XX, XXXX of XX.X% expenses mainly marketing, efforts despite in we the to collection Because increase selling year-ended receivable. a accounts of XX, for million $X.X XXXX. total $X in certain the additional resulting of the expenses additional policies, year to decrease of practices million reform require Selling decrease and and The ended provinces. personnel support December million in of sales the healthcare to product accounted XXXX. and was promotion for overall XX.X% sales from consulting in result compared our sales, the Our adjustments our compared

million, total December for compared General which and our XXXX. $X.X $X.X year XXXX administrative XXXX expenses XXXX of expenses ended respectively. and an to were revenues million XX.X% for represented in in million increase and XX.X% of and general $X administrative Our XX, the accounted

of of XXXX. XX, to $X.X the was expenses of accounts receivables year in XXXX million, the aging ended year-ended The $X.X million to Our XX, compensation represented the December of the increase XXXX. bad which $X.X for expenses due the was change compared debt mainly compared an bad increase debt December for in our XXXX XX, million to December

year XX, development XX, It the a $X Our the for to debt in of result was XXXX. the in form mainly $X.X and net and as net foreseeable such and the government of on in policies XX, six decrease Because respectively, $XX.X our have positive impairments XXXX ended cash and the the assets of consistency December in year we would for flow therefore medical December of been recognized Net December The in focusing a million, implemented increase five XXXX future, the the generate be management our intangible compared recently XXXX. December mainly were XX, identified loss impairment and was pharmaceutical expenses. of because million and to the loss that them mainly loss evaluations, to that December formulas $XX.X XXXX bad loss regarding certain year likely assets, for the million unable loss assessments intangible million impairment as the of ended made XX, of accordingly. ended formulas. was XXXX the maintenance impairment compared as company, on of our

million XXXX as cash as to respectively. from the and $X.X cash million, $X.X and was Turning balance million million XXXX December current the as XXXX XX, of December capital compared and X.X ratio XX, XX, of of company the XXXX. December sheet, X.X to and [ph] equivalents December of $X.X XX, at XX, September XXXX decreased times Working had $X December of XX, as XXXX, to

Overall, XX, $X.X in million, XXXX. of XXXX, December $X.X development Operator? will to XXXX. promote year-ended accounts receivables our that as million flow December million compared XX, XXXX, evaluation from up in was operating $X.X believes sales the to will we support call focusing that, to we compared for future. fair as our and shareholders XX, questions. business the of the December on our will Cash of and continue interest open With As net this now the was activities million $X our

Operator

Our Peter private Please from comes Instructions] Ceres question ask first the line question. investor. from your [Operator of -- [ph] a

Unidentified Analyst

questions. I have two

do long you've and this for promised everything good see opportunities with that again is, strategic on you can going investing company? you see way get learned business any a facilities the for lot question or doing First you’ve do as [ph] time, been money the mean, of with you any growing really I has CFDA in,

Zhilin Li

issued industry. did for as key those all be She believe policies takeaway as will thinks trafficking well go could upgrading national policy. of yes, should push in both issued in the of said, our further GMP international, a be should [indiscernible] our Li especially the very considered those as to that policies Ms. increase in from newly evaluation lot the be Chinese lender, since all Chinese manufacturing observe Ms. as to companies CFDA industry, to well issued she as countries newly upgrading considered entity players recently challenge policies as manufacturing Li pharmaceutical local standards.

order to of to go go confidence also this believe Li the position in international. opportunities fast our the potential gearing business us policy you. the try leverage So evaluation a evaluation. put consistent with in Ms. Thank get favorable and timing to our to and to touch environment

Unidentified Analyst

written be other that the when you over bills hospitals. I hospitals I their accounts question don’t the get chance there why receivable is, years, last And owned of understand get pay a had stated many, And you’ve state that or guess number out fair these owned I the don’t money some from may many to will ever back?

Zhilin Li

good methods number of collection extents company try accounts reform to has of have expected. we to yes, various we as the as Li, will significant the of kinds historical our receivable. of collect Thank receivable performance non-current, accounts issues as best that, receivables. recently tried policies. our to such collect background try as the not even Unfortunately the is Ms. company still accounts Anyway, you. non-aged well The

Operator

back There would questions I hand Instructions] the conference presenters. today's [Operator time. this further continue. like Please at are no to to

Sam Hsing

the for like on and this of the would participation On China we interest Team, you to company the in behalf call. Pharma thank your

potential you This from of Thanks. Pharma's investors full analysts. encouraging XXXX earnings call. always China, any our shareholders, and you year any travelling For welcome visitors China and we concludes to

Operator

participating. Ladies for our does and that today. you for gentlemen, conclude Thank conference

may all disconnect. You

Diana Huang

much. Thank very you

China Pharma (CPHI) 3 Apr 182017 Q4 Earnings call transcript